SecBot SecBot
SECBOTREPLAY Home › Report › LAB

LAB · Standard BioTools (LAB) filed an 8-K/A on July 29, 2026, attaching the…

STANDARD BIOTOOLS INC. · 425 filed Jul 29, 2026 at 08:16 ET

At the news

NEUTRALIMPACT 4/10

425 filed Jul 29, 2026 at 08:16 ET

Standard BioTools (LAB) filed an 8-K/A on July 29, 2026, attaching the full Share and Asset Purchase Agreement for the sale of its mass cytometry business to Multiplex Bio Inc., as previously announced on July 28, 2026. The deal includes a $5M base purchase price (paid via promissory note) plus up to $5M in contingent additional consideration tied to a future Qualifying Exit by Multiplex Bio. The transaction is a procedural step in LAB's broader restructuring ahead of its transformative reverse merger with Treeline Biosciences, and its closing is conditioned on the Treeline merger closing substantially concurrently.

  • LAB sells its mass cytometry business (CyTOF, Hyperion, Maxpar, Theia platforms) to Multiplex Bio Inc.
  • Base purchase price of $5,000,000, paid via a promissory note (Base Seller Note), subject to working capital and other adjustments.
  • Additional contingent consideration of $5,000,000 if Multiplex Bio achieves a Qualifying Exit (e.g., sale, IPO) within 10 years.
  • Target Working Capital set at $4,727,000.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access